Mutations in the P10 region of procaspase-8 lead to chemotherapy resistance in acute myeloid leukemia by impairing procaspase-8 dimerization

[1]  A. Florea,et al.  Overcoming chemotherapy drug resistance by targeting inhibitors of apoptosis proteins (IAPs) , 2017, Apoptosis.

[2]  J. Cortes,et al.  Treatment of Relapsed/Refractory Acute Myeloid Leukemia , 2017, Current Treatment Options in Oncology.

[3]  B. Zhivotovsky,et al.  Contrasting effects of glutamine deprivation on apoptosis induced by conventionally used anticancer drugs. , 2017, Biochimica et biophysica acta. Molecular cell research.

[4]  P. Souček,et al.  [Clinical and Functional Importance of Selected CASP8 and CASP9 Polymorphisms in Breast Carcinoma]. , 2016, Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti.

[5]  H. Kantarjian.  Acute myeloid leukemia—Major progress over four decades and glimpses into the future , 2016, American journal of hematology.

[6]  M. Keating,et al.  Expression of executioner procaspases and their activation by a procaspase-activating compound in chronic lymphocytic leukemia cells. , 2015, Blood.

[7]  A. Egloff,et al.  Caspase‐8 mutations in head and neck cancer confer resistance to death receptor‐mediated apoptosis and enhance migration, invasion, and tumor growth , 2014, Molecular oncology.

[8]  P. Brown,et al.  The Biology and Targeting of FLT3 in Pediatric Leukemia , 2014, Front. Oncol..

[9]  H. Nakajima,et al.  TET2 as an epigenetic master regulator for normal and malignant hematopoiesis , 2014, Cancer science.

[10]  James M. Bogenberger,et al.  Synergistic targeting of AML stem/progenitor cells with IAP antagonist birinapant and demethylating agents. , 2014, Journal of the National Cancer Institute.

[11]  J. Campisi.  The beginning of the end , 2013, Nature.

[12]  M. Levis.  FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013? , 2013, Hematology. American Society of Hematology. Education Program.

[13]  M. Soda,et al.  Cancer‐associated missense mutations of caspase‐8 activate nuclear factor‐κB signaling , 2013, Cancer science.

[14]  E. Estey,et al.  Significance of FAB subclassification of "acute myeloid leukemia, NOS" in the 2008 WHO classification: analysis of 5848 newly diagnosed patients. , 2013, Blood.

[15]  Q. Wei,et al.  Association between CASP8 and CASP10 polymorphisms and toxicity outcomes with platinum-based chemotherapy in Chinese patients with non-small cell lung cancer. , 2012, The oncologist.

[16]  A. Fazaeli,et al.  Bi-directional PCR allele-specific amplification (bi-PASA) for detection of caspase-8 -652 6N ins/del promoter polymorphism (rs3834129) in breast cancer. , 2012, Gene.

[17]  J. Rowe,et al.  Treatment for relapsed acute myeloid leukemia: what is new? , 2012, Current opinion in hematology.

[18]  Erinna F. Lee,et al.  Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia. , 2012, Genes & development.

[19]  E. Gottlieb,et al.  BID is cleaved by caspase-8 within a native complex on the mitochondrial membrane , 2011, Cell Death and Differentiation.

[20]  Y. Joo,et al.  Epigenetic methylation and expression of caspase 8 and survivin in hepatocellular carcinoma , 2010, Pathology international.

[21]  P. Krammer,et al.  A New C-Terminal Cleavage Product of Procaspase-8, p30, Defines an Alternative Pathway of Procaspase-8 Activation , 2009, Molecular and Cellular Biology.

[22]  T. Kang,et al.  Mutation of a Self-Processing Site in Caspase-8 Compromises Its Apoptotic but Not Its Nonapoptotic Functions in Bacterial Artificial Chromosome-Transgenic Mice1 , 2008, The Journal of Immunology.

[23]  John Calvin Reed,et al.  Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. , 2006, Cancer cell.

[24]  M. H. Werner,et al.  The structure of FADD and its mode of interaction with procaspase-8. , 2006, Molecular cell.

[25]  M. Tallman,et al.  Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. , 2005, Blood.

[26]  C. Bloomfield,et al.  Very Poor Survival of Patients with AML Who Relapse after Achieving a First Complete Remission: The Eastern Cooperative Oncology Group Experience. , 2005 .

[27]  J. Cayuela,et al.  Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotype. , 2005, Blood.

[28]  T. Naoe,et al.  Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia. , 2005, Blood.

[29]  M. Fey,et al.  Risk Assessment in Patients with Acute Myeloid Leukemia and a Normal Karyotype , 2005, Clinical Cancer Research.

[30]  W. Park,et al.  CASPASE-8 gene is inactivated by somatic mutations in gastric carcinomas. , 2005, Cancer research.

[31]  Paola Fazi,et al.  Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. , 2005, The New England journal of medicine.

[32]  S. Fröhling,et al.  CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  W. Park,et al.  Inactivating mutations of caspase-8 gene in colorectal carcinomas. , 2003, Gastroenterology.

[34]  Z. Fan,et al.  A Novel Single Amino Acid Deletion Caspase-8 Mutant in Cancer Cells That Lost Proapoptotic Activity* , 2002, The Journal of Biological Chemistry.

[35]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[36]  G. Evan,et al.  Caspase‐8 in Apoptosis: The Beginning of “The End”? , 2000, IUBMB life.

[37]  J C Reed,et al.  IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. , 1998, Cancer research.

[38]  Brent R. Stockwell,et al.  An Induced Proximity Model for Caspase-8 Activation* , 1998, The Journal of Biological Chemistry.

[39]  A. Jemal,et al.  Cancer statistics, 2017 , 2017, CA: a cancer journal for clinicians.

[40]  D. Ettinger,et al.  Taxol (paclitaxel) in the treatment of lung cancer: the Eastern Cooperative Oncology Group experience. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[41]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[42]  Thomas D. Schmittgen,et al.  Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2 2 DD C T Method , 2022 .